Monte Rosa Therapeutics
GLUE
52 hedge funds and large institutions have $560M invested in Monte Rosa Therapeutics in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 7 reducing their positions, and 11 closing their positions.
257% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 7
7.75% more ownership
Funds ownership: 78.13% → 85.88% (+7.7%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
2% less funds holding
Funds holding: 53 → 52 (-1)
25% less capital invested
Capital invested by funds: $742M → $560M (-$182M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.7M |
| 3 |
BlackRock
New York
|
+$10.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.36M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$10.8M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$6.13M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$3.06M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$1.95M |
| 5 |
E
Ergoteles
New York
|
-$1.52M |
GLUE Hedge Fund Activity: Q1 2022 in Review
52 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q1 2022, worth a combined $560M — down 25% from $742M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of GLUE and 10 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 25 added.
The largest buyer was Vanguard Group, adding an estimated $26.7M. The largest seller was Jennison Associates, exiting entirely with an estimated $10.8M sold.
- 52 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q1 2022, down from 53 in Q4 2021.
- Funds reported $560M of Monte Rosa Therapeutics stock for Q1 2022, down 25% quarter-over-quarter.
- 10 funds opened new Monte Rosa Therapeutics positions in Q1 2022 and 11 closed out, a net change of -1 holder.
- The largest Monte Rosa Therapeutics buyer in Q1 2022 was Vanguard Group, an estimated $26.7M added.
- The largest Monte Rosa Therapeutics seller in Q1 2022 was Jennison Associates, an estimated $10.8M sold.
Based on aggregated 13F filings for Q1 2022.